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Abstract: One hundred million deaths were caused by tobacco in the 20
th century, and it is 
estimated that there will be up to one billion deaths attributed to tobacco use in the 21
st 
century. Chronic obstructive pulmonary disease (COPD) is rapidly becoming a global 
public health crisis with smoking being recognized as its most important causative factor. 
The most effective available treatment for COPD is smoking cessation. There is mounting 
evidence that the rate of progression of COPD can be reduced when patients at risk of 
developing the disease stop smoking, while lifelong smokers have a 50% probability of 
developing COPD during their lifetime. More significantly, there is also evidence that the 
risk of developing COPD falls by about half with smoking cessation. Several 
pharmacological interventions now exist to aid smokers in cessation; these include nicotine 
replacement therapy, bupropion, and varenicline.  All pharmacotherapies for smoking 
cessation are more efficacious than placebo, with odds ratios of about 2. Pharmacologic 
therapy should be combined with nonpharmacologic (behavioral) therapy. Unfortunately, 
despite the documented efficacy of these agents, the absolute number of patients who are 
abstinent from smoking at 12 months of follow-up is low.  
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1. Introduction 
 
According to the World Health Organization (WHO), one hundred million deaths were caused by 
tobacco in the 20
th century, and if current trends continue, there will be up to one billion deaths 
attributed to tobacco use in the 21
st century. There are more than one billion smokers in the world, and 
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globally the use of tobacco products is increasing (Figure 1), with the epidemic shifting to the 
developing world. More than 80% of the world’s smokers live in low and middle income countries. It 
is estimated that tobacco use kills 5.4 million people a year and accounts for 10% of adult deaths 
worldwide, with up to 50% of smokers dying from a tobacco-use related disease. Unchecked, tobacco-
related deaths will increase to more than eight million a year by 2030, and 80% of those deaths will 
occur in developing countries. Tobacco use is a risk factor for six of the eight leading causes of deaths 
in the world including respiratory and cardiovascular diseases, stroke and several malignant diseases 
[1].  
 
Figure 1. Global cigarette consumption. Increasing trend in the consumption of cigarettes 
(1880-2000)*. 
 
*Modified from Mackay, J.; Eriksen, M. The Tobacco Atlas © World Health 
Organization Publications. 
 
Chronic obstructive pulmonary disease (COPD) is a major and growing cause of morbidity and 
mortality in countries at all levels of economic development [2, 3] with smoking being recognized as 
its most important causative factor [1, 3]. 
According to the WHO estimates, 80 million people in the world have moderate to severe COPD. 
More than 3 million people died of COPD in 2005, which corresponds to 5% of all adult deaths 
globally and it is estimated that by 2020 it will become the third leading cause of death worldwide [4]; 
this chronic disease is however, barely even acknowledged in the health statistics of many countries. 
Many patients remain undiagnosed, experience high levels of symptoms, their quality of life is often 
poor and they usually die prematurely of it or its complications [5-8].  
Although cigarette smoking is the most commonly encountered tobacco-related risk factor for 
COPD [4], other types of tobacco smoking popular in various countries are also risk factors for COPD 
[9, 10] and air pollution resulting from the burning of wood and other biomass fuels, has also been 
identified as a COPD risk factor [4]. Passive exposure to cigarette smoke may also contribute to the 
development of COPD by increasing the lung total burden of inhaled particles and gases [11]. 
There is now evidence that most smokers develop some respiratory impairment due to COPD [12, 
13]. One recent study addressing this issue [14] reported that 50% of smokers eventually develop 
COPD, as defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Int. J. Environ. Res. Public Health 2009, 6          
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guidelines [4]. This finding is of major clinical significance, in that it provides a scientific basis for the 
advice that can now be given to smokers that if they continue smoking lifelong, they have at least a 
one in two chances of developing COPD [12].  
The costs of COPD to health services and society are substantial. Consultation rates in primary care 
are high and exacerbations of COPD are one of the most common causes of hospital admission. In 
developed countries, exacerbations of COPD account for the greatest burden on the health care system. 
In the European Union, the total direct costs of respiratory disease are estimated to be about 6% of the 
total health care budget, with COPD accounting for 56% (€38.6 billion) of this cost. In the United 
States in 2002, the direct costs of COPD were $18 billion and the indirect costs totaled $14.1 billion 
[4, 15]. 
 
2. Pathogenesis and Pathophysiology of Tobacco Induced Lug Injury. 
 
Cigarette smoke contains an extremely high concentration of oxidants. The reactive oxidant 
substances generated by smoking induce inflammation in the lung and its airway [16]; cigarette 
smoking causes an inflammatory process in the central airways, peripheral airways, and lung 
parenchyma, which is present even in smokers with normal lung function [17]. Studies have shown 
that in bronchial biopsies obtained from central airways, smokers have chronic inflammatory changes, 
with increased numbers of specific inflammatory cell types in different parts of the lung, and structural 
remodeling resulting from repeated injury and repair [18].  
The exact role of smoking cessation on the airway inflammation process in COPD is still unknown. 
Cross-sectional studies suggest that there is still ongoing inflammation in COPD even after smoking 
cessation [19]. In general, the inflammatory and structural changes in the airways increase with disease 
severity and persist despite smoking cessation.  
It is intriguing why airway inflammation is not resolved in COPD patients after 1 year of smoking 
abstinence, and even increases in some aspects. One explanation is that an inflammatory trigger 
persists after smoking cessation, keeping a local inflammatory response intact [20]. The persistent 
inflammation in chronic obstructive pulmonary disease may be, at least partly, related to repair of the 
smoke-induced tissue damage in the airways. It remains to be determined which parts of the observed 
inflammatory changes are beneficial and which harmful [20, 21]. A recently suggested hypothesis is 
that COPD may have an autoimmune component, which contributes to the airway inflammation even 
after smoking cessation [22]. These auto-antibodies may be directed against antigens present in 
tobacco or against endogenous auto-antigens that result from the smoking-induced inflammatory and 
oxidative lung injury [23]. 
 
3. Smoking Cessation and COPD 
 
Smoking cessation is the single most effective—and cost-effective—treatment for COPD. 
Furthermore, smoking cessation is associated with a reduction in the risk of developing stroke, 
coronary heart disease, several types of cancer, and it is associated to an increased life expectancy 
[24].  Int. J. Environ. Res. Public Health 2009, 6          
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Despite the ongoing inflammatory process, there is increasing evidence that the rate of development 
of COPD can be reduced when patients at risk of developing the disease stop smoking [25].  
The first indications came from longitudinal cohort studies which showed that subjects who 
continued to smoke had a much steeper decline in lung function than those who had stopped smoking 
[26, 27].  
The Lung Health Study confirmed that smoking cessation could reduce this smoking-related 
precipitous decline in lung function [28]. It was a randomized clinical trial designed to determine the 
potential benefits of smoking cessation. All participants had, as an inclusion criterion, asymptomatic 
airway obstruction. The special intervention participants received a smoking cessation program and 
were compared with usual care participants. Vital status was followed up to 14.5 years. The smoking 
intervention program consisted of a 10-week smoking cessation program that included a strong 
physician message and 12 group sessions using behavior modification and nicotine gum, plus either 
ipratropium or a placebo inhaler. At 5 years, 21.7% of special intervention participants had stopped 
smoking since study entry, compared with 5.4% of usual care participants. Smoking intervention 
participants had smaller declines in FEV-1 than usual care participants. Men who quit at the beginning 
of the study had an FEV-1 rate of decline of 30.2 mL/year, whereas women who quit declined at 21.5 
mL/year. Men continuing to smoke throughout declined by 66.1 mL/year, and women continuing to 
smoke declined by 54.2 mL/year. More importantly, all-cause mortality was significantly lower in the 
special intervention group than in the usual care group (8.83 per 1000 person-years vs. 10.38 per 1000 
person-years; p=0.03) [29].   
It has been shown that repeated attempts to quit smoking, even with subsequent relapses, can 
prevent loss of lung function, especially in patients with mild COPD [30], and prolonged abstinence is 
also associated to a reduction in pulmonary symptoms [31]. 
If a smoker with advanced COPD smoking, he/she will not recover lost lung function, but the 
subsequent rate of decline is likely to revert towards normal [32]. Smoking cessation at an early stage 
of the disease has shown to improve prognosis [28, 32-33], and there is evidence that smoking 
cessation at an early stage of COPD is more effective than in the later stages [34]. 
Smokers seem to be intrinsically more motivated to stop smoking if they realize that their 
respiratory complaints are caused by smoking and that they are at risk of developing COPD [35]. In a 
recent study, smoking cessation rates were compared between smokers with COPD and smokers with 
normal lung function. During follow-up, the abstinence rates were significantly higher in smokers with 
COPD than in smokers with normal lung function [36].  
 
4. Smoking Cessation Intervention Process. 
 
Tobacco dependence is a chronic condition that often requires repeated intervention to succeed 
[37]. Once users are dependent on tobacco, quitting is extremely difficult. Nicotine dependence 
resulting from tobacco use hinders efforts to sustain abstinence from tobacco for a prolonged period. 
Many users make multiple attempts to quit, often without the assistance that could significantly 
increase their chances of success. Studies have shown that a considerable number of smokers want to 
stop smoking, but a significant proportion of them have never tried [38]. A large proportion of all 
smokers are in the stage of contemplation or the stage of preparation. Most smokers go through several Int. J. Environ. Res. Public Health 2009, 6          
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stages before they finally take the decision to make a cessation attempt and at last succeed with their 
intentions and stop smoking. Smoking cessation advice or other interventions appear to have their 
effect by triggering a cessation attempt. Each year about 2% of smokers succeed in quitting on their 
own initiative [39].  
Smoking cessation is challenging and behavioral interventions alone have had only modest success; 
as a result drug therapy has been increasingly relied upon to assist in smoking cessation. The most 
common of these pharmacologic interventions has been nicotine replacement therapy (NRT) [40]. 
More recently, attention has focused on the use of anti-depressant therapy [4, 41]. Pharmacologic 
smoking cessation aids are recommended for all smokers trying to quit, unless contraindicated [42]; 
smokers should also be provided with counseling when attempting to quit [39]. Family physicians can 
play an important role in the smoking cessation process, given that 70% of smokers consult family 
physicians annually [43].  
As mentioned, most smokers who attempt to quit do not utilize cessation aids, and as a result, they 
are usually unsuccessful with two-thirds relapsing within 48 hours [44]. For this reason, all smokers—
including those who may be at risk for COPD as well as those who already have the disease — should 
be offered the most intensive smoking cessation intervention possible. Even a brief period of 
counseling at the doctor’s office to urge a smoker to quit, results in smoking cessation rates of 5 to 
10% [45-47]. At the very least, this should be done for every smoker at every health care provider visit 
[48-51]. The rate of successful smoking cessation at one year is of 3-5% when the patient simply tries 
to stop, from 7-16% if the smoker undergoes behavioral intervention and up to 24% when receiving 
pharmacological treatment plus behavioral support. Recently, several meta-analyses have shown that 
all current pharmacotherapies for smoking cessation are twice as likely more efficacious than placebo 
[52-54].  
 
Table 1. Efficacy of pharmacologic treatment for smoking cessation *. 
Treatment Experimental  group  Control Group  OR (CI95%) 
Nicotine gum  19.5%  11.5%  1.66 (1.52, 1.81) 
Nicotine patch  14.6%  8.6%  1.81 (1.63, 2.02) 
Nicotine inhaler  17.15  9.1%  2.14 (1.44, 3.18) 
Bupropion  20.0%  10.2%  1.94 (1.72, 2.19) 
Varenicline 23.0%  10.3%  2.66  (1.72.4.11) 
*Modified from Schmelzle, J., et al. [43] 
 
Pharmacologic agents are classified as first-line pharmacotherapy, which includes nicotine 
replacement therapy, bupropion and varenicline and second-line agents such as nortriptyline, a 
tricyclic antidepressant agent, and clonidine, an antihypertensive drug [54]. 
 
5. Nicotine Replacement Therapy 
 
Most regular smokers are addicted to nicotine. When a subject smokes a cigarette, nicotine will get 
into the bloodstream and almost immediately stimulate the brain. In regular smokers, when the blood 
level of nicotine decreases, withdrawal symptoms such as restlessness, increased appetite, inability to 
concentrate, irritability, dizziness, and nicotine craving will develop. These symptoms begin within a Int. J. Environ. Res. Public Health 2009, 6          
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few hours after having the last inhalation of tobacco smoke; if they are not relieved by smoking a 
cigarette, withdrawal symptoms will increase in severity. Nicotine replacement therapies will allow the 
smoker to maintain stable nicotine levels in the bloodstream to avoid withdrawal symptoms without 
smoking. 
Nicotine replacement therapies (NRTs) available include nicotine gum, patches, and inhalers. These 
therapies aid in smoking cessation by replacing the nicotine-mediated neuropharmacologic effects 
achieved by smoking [39]. Authors of a systematic review and meta-analysis which reviewed 
randomized trials of NRT compared with placebo or no treatment, and that had follow-up periods of 6 
months or longer, determined that NRT doubles the likelihood of smoking cessation compared with no 
therapy (OR 1.77, 95% confidence interval [CI] 1.66-1.88) [40]. Evidence also indicates that the 
nicotine patch combined with another NRT is more effective than any single NRT [55, 56].  
The potential side effects of nicotine gum include dyspepsia, singultus (hiccups) and a mandible 
pain. Nicotine patches are associated with cephalea, dizziness and nausea, sleep disturbances, and rash 
at the site of patch application. Adverse effects experienced by users of nicotine inhalers include throat 
and nasal irritation, rhinorrhea, sneezing, and coughing [57].  
 
6. Bupropion 
 
Bupropion was originally launched as a smoking cessation aid in 1997 and has now been approved 
in more than 50 countries [58]. It blocks the reuptake  of dopamine and norepinephrine, which is 
thought to be the mechanism behind its effect on smoking cessation [59]. In a systematic review and 
meta-analysis of 31 bupropion trials in which bupropion was the sole agent used for cessation 
(compared with placebo or no pharmacotherapy), with 6 months follow-up or longer, the reviewers 
found the likelihood of cessation almost doubled with bupropion therapy [40, 60].  
Bupropion alone or in combination with the nicotine patch has been found to significantly increase 
long-term cessation rates compared with the patch alone. The abstinence rates at 12 months were 15.6 
percent in the placebo group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent 
in the bupropion group (P<0.001), and 35.5 percent in the group given bupropion and the nicotine 
patch (P<0.001). The greater abstinence rate with combination therapy (bupropion+nicotine patch) 
compared with bupropion alone, however, was not statistically significant [56]. 
The most common side effects associated with bupropion are dry mouth and insomnia. 
Additionally, the risk of seizures is thought to be 1 in 1000, and is associated with risk factors such as 
seizure disorders and eating disorders [61]. Only two seizures episodes were reported in the bupropion 
trials. However, the small number of observed seizures is likely due to the exclusion of patients at risk 
for seizures before randomization. 
 
7. Varenicline 
 
Varenicline is the first partial agonist of the α4β2 nicotinic acetylcholine receptor to be developed. 
The dependency effects of nicotine are thought to be mediated at these receptors [62, 63]. Varenicline 
works by stimulating dopamine, which results in reduced cravings and withdrawal symptoms. The 
drug also blocks nicotine receptors, which prevents the dopamine release associated with nicotine Int. J. Environ. Res. Public Health 2009, 6          
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consumption [63, 64]. Varenicline might diminish withdrawal symptoms through an agonist effect and 
reduce craving through an antagonist effect; with nicotine exposure, the receptor occupancy of 
varenicline is expected to block the reinforcing effects of nicotine [65]. 
The most common side effect associated with varenicline is nausea. Other side effects include 
insomnia and abnormal dreaming [66, 67]. 
Recently, several trials have demonstrated the effectiveness of varenicline, in improving cessation 
rates [65, 66, 68-70]. Bupropion has been compared with varenicline in recent head-to-head 
randomized controlled trials [66, 68, 70]. These trials consistently favored varenicline. After pooling 
these data, it was found that rates of smoking abstinence associated with varenicline were about twice 
those associated with bupropion.  
However, from the time of initial trials, varenicline has been associated with significant psychiatric 
adverse effects [71].  Recently the FDA issued two Med Watch advisories regarding reports of 
behavioral changes in patients taking varenicline. These have included erratic behavior, new onset of 
depressed mood, agitation, suicidal ideation, suicidal attempts, and completed suicides within days to 
weeks of initiating varenicline. Not all the individual affected had pre-existing histories of psychiatric 
illness [72]. There have been two recent published case reports of varenicline exacerbating symptoms 
of schizophrenia [73] and inducing a manic episode in a patient with bipolar disorder [74].  As 
mentioned, varenicline displaces nicotine from acetylcholine receptors, which in turn produces low to 
moderate levels of dopamine release, and stimulates the central nervous mesolimbic dopamine system. 
This may upset the balance in cholinergic-adrenergic tone, which has been implicated in the 
physiology of mania [71].  
In summary varenicline seems to be the most effective of the available pharmacological agents for 
smoking cessation; however, the extensive exclusion criteria for most of these trials, the substantially 
different losses to follow up between groups, and the fact that most of these trial are funded by the 
industry might affect the trustworthiness and generalizability of these results [43]. 
Despite the early efficacy of these pharmacotherapies, the number of patients that remain abstinent 
from smoking at 1 year follow-up is low. Most of the randomized controlled trials report a point 
prevalence of abstinence at 12 months to be well under 30% among patients in the treatment groups. 
With continuous abstinence as the outcome measure, the rate of abstinence is even lower [64].  
 
8. Nonpharmacologic Treatment 
 
Nonpharmacologic cessation strategies include brief interventions, such as patient education and 
advice, behavioral therapy, self-help materials, and telephone counseling [65]. A review of randomized 
or quasi-randomized trials of individual behavioral counseling for smoking cessation by trained 
therapists with 6 months or longer follow-up indicated that individual counseling was more effective 
than no intervention at all. Counseling usually consists of one or more face-to-face sessions, often 
accompanied by telephone contact for support [66]. Evidence shows that group counseling is more 
effective than self-help and other less intensive intervention methods for smoking cessation [77]. It is 
unclear if group counseling is more effective than individual counseling, but it is more effective than 
no intervention [78]. Self-help materials might improve quit rates among smokers compared with those 
who receive no intervention, but the effect is generally small [79]. Proactive telephone counseling, in Int. J. Environ. Res. Public Health 2009, 6          
 
216
which the counselor initiates client contact, enhances the benefit of telephone counseling in 
comparison to reactive counseling, in which the client initiates contact. Multiple sessions of telephone 
counseling improve quit rates [80].  
Web-based cessation programs have as well been found to be effective in smoking cessation [81, 
82],  however, more research is needed in this area [83]. 
 
9. Combined Therapy 
 
Pharmacotherapy and counseling should be used in conjunction to further improve the chances of 
successful cessation [42]. Brief counseling combined with NRT has been found to be more effective 
than counseling alone in a randomized study of hospital patients receiving smoking cessation 
interventions [84, 85]. In a randomized study of telephone counseling combined with nicotine patch 
therapy, individuals who received both counseling and NRT had significantly greater abstinence rates 
compared with those who received NRT alone [86, 87].  
How effective are the smoking cessation interventions in COPD patients? As mentioned the Lung 
Health Study (that included asymptomatic smokers with airway obstruction) reported that at 5 years, 
21.7% of special intervention participants had stopped smoking since study entry, compared with 5.4% 
of usual care participants [28]. A recent Crochane review revealed the effectiveness of psychosocial 
interventions combined with pharmacological intervention compared to no treatment in COPD 
patients: psychosocial interventions combined with NRT versus no treatment increased the probability 
of success at a 5 year follow-up by four-fold (Relative risk= 4.19, 95% CI 3.41 to 5.15) [88].  
 
10. Strategy for Smoking Cessation 
 
Health care providers are key to the delivery of smoking cessation messages and interventions. 
Health care workers should encourage all patients who smoke to quit, even those patients who come to 
the health care provider for unrelated reasons and do not have symptoms of COPD, evidence of 
airflow limitation, or other smoking related disease. 
The strategy for smoking cessation has utilized a mnemonic system based on the five “A’s” [4]: 
1.  ASK: Systematically identify all tobacco users at every visit. Write a patient's smoking status 
in the medical chart under vital signs. Implement a system that ensures that, for every patient at 
every clinic visit, tobacco-use status is queried and documented. Ask patients about their desire 
to quit, and reinforce their intentions. 
2.  ADVISE: Strongly urge all tobacco users to quit. In a clear, strong, and personalized manner, 
urge every tobacco user to quit. Motivate patients who are reluctant to quit.  
3.  ASSESS: Most individuals go through several stages (precontemplation, contemplation, 
recycling) before they stop smoking. Determine willingness to make a quit attempt. Ask every 
tobacco user if he or she is willing to make a quit attempt at this time.  
4.  ASSIST: Aid the patient in quitting. Help the patient with a quit plan; help motivated smokers 
set a quit date. Provide practical counseling; provide, if available, intra-treatment social 
support; six first-line pharmacotherapies for tobacco dependence— bupropion SR, varenicline, Int. J. Environ. Res. Public Health 2009, 6          
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nicotine gum, nicotine inhaler, nicotine nasal spray, and nicotine patch—are effective and at 
least one of these medications should be prescribed in the absence of contraindications. 
5.  ARRANGE: Schedule follow-up contact, either in person or via telephone. Encourage 
relapsed smokers to try quitting again. Tobacco dependence is a chronic condition that warrants 
repeated treatment until long-term or permanent abstinence is achieved.  
There is limited data to guide clinicians in recommending one type of pharmacotherapy over 
another, the use of combinations, or how to match individual smokers to a particular form of therapy. 
Recently a Delphi approach was used to build consensus among a panel of international experts from 
various health disciplines with the purpose of developing decision rules for clinicians to guide 
differential prescribing practices and tailoring of pharmacotherapy for smoking cessation [89]. Factors 
that should be considered in prescribing pharmacotherapy include level of scientific evidence, patient 
preference and patient previous experience. The decision to prescribe combinations should be based on 
a history of failed attempts with monotherapy, patients with breakthrough cravings despite treatment 
and level of tobacco dependence. Other factors that should be taken into account on selection of 
pharmacotherapy include the potential impact on comorbidities and the presence of contraindications. 
There appears to be good justification for "off label" use such as higher doses of NRT or combination 
therapy in certain circumstances. 
 
11. What can We Expect in the Near Future? 
 
Although recent data suggest that current pharmacotherapy for smoking cessation is superior to 
placebo for treating nicotine dependence, a majority of smokers fail to maintain long-term abstinence 
from smoking. Thus, continued investigation of novel medications for nicotine dependence remains a 
critical priority. Promising agents include new non-nicotine-replacement pharmacotherapies [90-93] 
such as selegiline (a monoamine oxidase type B [MAO-B] inhibitor), fluoxetine (an antidepressant of 
the selective serotonin reuptake inhibitor [SSRI] class), naltrexone (an opioid receptor antagonist used 
primarily in the management of alcohol dependence and opioid dependence) and mecamylamine (a 
ganglionic blocker); other strategies include the development of a vaccine against nicotine dependence 
[94] and pharmacogenetic approaches to smoking cessation [95, 96]. 
 
12. Conclusions 
 
Tobacco use kills more than five million people a year and accounts for 10% of adult deaths 
worldwide. COPD is a major and growing cause of morbidity and mortality with smoking being 
recognized as its most important causative factor. Several meta-analyses have shown that all 
pharmacotherapies for smoking cessation are twice as likely more efficacious than placebo with an 
abstinence rate in the 25-30% range at one year when pharmacological treatment and behavioral 
support are combined. Unfortunately, in spite of the initial efficacy of these pharmacotherapies, the 
number of patients that remain abstinent from smoking at 1 year follow-up is low (range 16-25%) [64]. 
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